RecruitingPhase IIEN originalLeukemia

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

NCT05827549Original on ClinicalTrials.gov ↗
⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • •Pacjenci w wieku od urodzenia do 22 lat w momencie nawrotu choroby.
  • •Histologiczne potwierdzenie ostrej białaczki limfoblastycznej (B-ALL lub T-ALL).
  • •Pierwszy nawrót białaczki limfoblastycznej, obejmujący szpik kostny lub inne miejsca.
  • •Pacjenci, którzy nigdy nie przeszli przeszczepu komórek macierzystych.
  • •Pacjenci, którzy nigdy wcześniej nie otrzymali leku blinatumomab.
  • •Dobra praca nerek i wątroby.
  • •Dobra praca serca (wskazana przez echokardiogram).
  • •Dobry ogólny stan zdrowia pacjenta (wg skali Lansky'ego lub Karnofsky'ego).

✗ Disqualifies

  • •Pacjenci z białaczką/chłoniakiem Burkitta lub dojrzałą białaczką komórek B.
  • •Pacjenci z białaczką limfoblastyczną z dodatnim chromosomem Philadelphia (Ph+ ALL).
  • •Pacjenci z nawrotową ostrą białaczką limfoblastyczną z niedoborem CD19 (brak CD19 na komórkach B).

Simplified criteria — AI translation

Trial details

Minimum age
1 Year
Maximum age
22 Years
Last updated (source)
July 29, 2026
Sex
No restrictions

Therapies / drugs in trial

Reinduction(4weeks)Cosolodation 1st(3weeks)Consolidation 2nd(3weeks)Blinatumomab 1st(High Risk Group)_4 WeeksBlinatumomab 2nd (High Risk Group)_4 WeeksBlinatumomab-Salvage 1st (Very High Risk Group)_4 WeeksBlinatumomab-Salvage 2nd (Very High Risk Group)_4 WeeksIntensification courseMaintenance(12 Weeks/Cycle)Stem Cell Transplantation

Locations (10)

Kyungpook National University Chilgok Hospital

Daegu, South Korea

Chungnam National University Hospital

Daejeon, South Korea

Chonnam National University Hwasun Hospital

Hwasun, South Korea

Jeju National University Hospital

Jeju City, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul saint Mary's Hospital

Seoul, South Korea

Pusan National University Yangsan Hospital

Yangsan, South Korea

Trial contact

Ho Joon Im

hojim@amc.seoul.kr+82-10-6231-1573

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Open original on ClinicalTrials.gov ↗Have questions? Contact us

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.